24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Epitomee
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
15:16
"We see the biggest opportunities in residential construction"
15:05
"Our goal is to produce clean, affordable energy that supports the economy"
14:52
Once $5 billion IPO bound, Cybereason merges with Trustwave amid decline
12:59
"We’re effectively democratizing access to computing power through our platform"
More stories
Buzz
Most popular
Daily
Weekly
1
Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"
2
Is your solitaire opponent actually a bot?
3
Cloudera acquires Israeli startup Octopai to advance metadata and AI integration
4
Former Snyk founder Guy Podjarny secures $125M for AI-powered software startup Tessl
5
CyberArk and Wiz join forces to enhance cloud security in multi-cloud environments
More news
Epitomee
4 stories about Epitomee
Epitomee surges 200% in two days on FDA approval for weight loss pill
16.09.24
|
Adiel Eithan Mustaki
Investors are hopeful, but the company must now face an uphill battle in a crowded market.
Weight loss pill maker Epitomee’s stock sinks 70% after Nestlé cancels agreement
04.12.23
|
Adiel Eithan Mustaki
The Swiss conglomerate notified Epitomee that it has decided not to market its product as the clinical trial results measuring the disparity in the weight loss rate between patients who took the pill and the control group did not reach the previously agreed upon success level
Weight loss pill success sparks stock surge at Epitomee Medical
04.09.23
|
Adiel Eithan Mustaki
The company, which has not yet published the full results of its study, plans to seek FDA approval via the 510(k) pathway
Weight-Loss Pill Developer Epitomee Raises $8 Million
10.04.19
|
CTech
Epitomee develops an orally administered capsule that affects the stomach through mechanosensory stimulation, encouraging prolonged gastric emptying and giving patients the sensation of being full
Please ensure Javascript is enabled for purposes of
website accessibility